Actavis/Actavis introduction

< ' , bAcavis (Foshan) Pharmaceutical Co., Ltd.
b.//_bb_.) Company name Actavis (Foshan) Pharmaceutical Co., Ltd. Headquarters address New Jersey, United States Company type Pharmaceutical company predecessor Foshan Pharmaceutical Factory
< - b.rr/_.) - Company Profile
,rr, . , r. , r, , b, , rr,

< - b.rr/ _.) - Company Development
, r. , , , . b ,
Actavis Group is a pharmaceutical company headquartered in New Jersey, USA. It is one of the strongest pharmaceutical companies in the world and has a global name. The third largest pharmaceutical company, its business covers many countries or regions around the world. There are a variety of products currently in production and on sale, as well as products under development and registration, involving central nervous system, digestion, cardiovascular, metabolism, anti-infection, respiratory and other fields.
Actavis (Foshan) Pharmaceutical Co., Ltd. is the R&D, production and sales base of Actavis Group in my country. Its predecessor was the Foshan Pharmaceutical Factory established in 2000, and later passed through the Australian Kangbaoshun (Foshan) Pharmaceutical Co., Ltd. The company, American Alai (Foshan) Pharmaceutical Co., Ltd., developed into Actavis (Foshan) Pharmaceutical Co., Ltd. at the end of the year.
Actavis insists on implementing the highest standards in research and development, production and service. We look forward to working with dealers across the country to provide customers with good medicines of EU quality and Chinese prices. As an important part of the development strategy of the Actavis Group, my country's mainland business has a bright future and will certainly make infinite contributions to the Group becoming a better generic drug company.
When Pfizer and other pharmaceutical giants are paying more and more attention to new markets, especially the Chinese market, some people are doing the opposite. Paolo Bisaro, CEO of Actavis (), the world's third largest copycat drugmaker, announced on Thursday , the company will completely withdraw from the Chinese market.

Sales last year were expected to reach US$100 million
News from Zhongkang Information shows that if you are unfamiliar with the name Actavis, then the name Watson Pharmaceuticals will definitely make you Understand that this copycat drug company, which was the first to imitate Lipitor and received widespread attention when the Lipitor patent expired, is the predecessor of Actavis. After Watson Pharmaceuticals completed the acquisition of Actavis for US$100 million in stock and cash on September 3, 2017, the new company was named Actavis.
After this acquisition, Actavis became the third largest copycat drug dealer in the world. In the following three years, Actavis appeared for the first time among Fortune's top American companies, ranking third. Today, the company makes copies of Lipitor and Vicodin, has popular ADHD and low-testosterone treatments, and has a sizable oral contraceptive business.
According to "Pharmaceutical Manager" news, Actavis' annual sales in three years are expected to reach 100 million US dollars. Today, Actavis has launched multiple products around the world, with promotional stores in many countries. The global headquarters of the company group has moved to Dublin, Ireland (Ireland is favored by pharmaceutical companies for its tax policy), and its administrative headquarters is located in The town of Parspany, New Jersey, USA, has more than 100 employees around the world.

In 2018, he made a high-profile statement
Optimistic about the Chinese market
As for the Chinese market, in 2018, Actavis invested US$100 million to acquire the global generic drug business of the American company Alai. And replaced Foshan Yalai and officially entered my country. At that time, Tom, president of Actavis Asia Pacific, said frankly that my country's pharmaceutical market has reached the top in the global rankings and has reached a growth rate. Actavis's entry into my country is a sign of the huge potential of my country's generic drug market. Actavis will also target opportunities and acquire some potential domestic companies and products.
In March 2019, Actavis my country President Gao Renbi once again stated in a high-profile interview with the media: He is full of confidence in the Chinese market. In the next three years, two new products will be launched every year. After three years, we will strive to There are - one category on the market every year.
However, this decision to withdraw from the Chinese market is contrary to the company's argument last year. According to Bloomberg, Bizarro said at a JP Morgan health care conference that this withdrawal from my country does not require much attention and investors should not be nervous. He also stated that Actavis’ current business in my country is still relatively small, with only a few hundred employees and annual profits of 10,000 to 10,000 euros (10,000-10,000 yuan). The company has successfully sold one of its businesses before and is now preparing to sell another one as well.

Copy drug market
Just looks beautiful
Although it is said that the market is small, the industry said that as my country's national drug bidding system continues to follow the low-price route, and the country begins to investigate The bribery behavior of foreign-funded pharmaceutical companies in my country and the living space of foreign-funded copycat pharmaceutical companies in the country are constantly being tightened. The withdrawal of Actavis from our country is not a surprise.
Bisaro has also stated that because my country’s business environment is not friendly, although my country has many potential customers, the government has made the market environment very difficult for the company to develop its business. He said: If we want to allocate resources, we will choose the market where we can get the maximum return with the minimum risk, but it is undoubtedly too risky to choose the Chinese market.
In fact, in addition to Actavis, there are many multinational copycat pharmaceutical companies that have announced their withdrawal from the Chinese market in recent years. In 2017, Germany's Merck sold all of its Merck & Arpels subsidiary located in Zhongshan, Guangdong, and withdrew from my country's copycat drug market. In 2017, India's largest copycat drug company Ranbaxy announced the termination of its joint venture with a Chinese company and transferred its holdings of Guangzhou Nanxin Pharmaceutical Co., Ltd. After selling all the company's shares and withdrawing from the pharmaceutical business in my country for three years, AstraZeneca quietly announced that it would suspend investment in my country's branded copycat drug market, and its Taizhou production base, which cost hundreds of millions of dollars, also adjusted its production direction.
' , .
' , .
' , .
' , .
' , .